141 related articles for article (PubMed ID: 20018309)
1. Editorial comment.
Williams SG
J Urol; 2010 Feb; 183(2):639; discussion 639-40. PubMed ID: 20018309
[No Abstract] [Full Text] [Related]
2. Editorial comment.
Pinkawa M
J Urol; 2010 Feb; 183(2):639; discussion 639-40. PubMed ID: 20018310
[No Abstract] [Full Text] [Related]
3. Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy?
Stone NN; Marshall DT; Stone JJ; Cesaretti JA; Stock RG
J Urol; 2010 Feb; 183(2):634-9. PubMed ID: 20018308
[TBL] [Abstract][Full Text] [Related]
4. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
Mabjeesh NJ; Chen J; Stenger A; Matzkin H
Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors of acute urinary retention requiring catheterization following 125I prostate brachytherapy.
Ohashi T; Yorozu A; Toya K; Saito S; Momma T
Jpn J Clin Oncol; 2006 May; 36(5):285-9. PubMed ID: 16698803
[TBL] [Abstract][Full Text] [Related]
6. Editorial comment.
Roach M
J Urol; 2010 Feb; 183(2):551. PubMed ID: 20006855
[No Abstract] [Full Text] [Related]
7. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.
Valero J; Cambeiro M; Galán C; Teijeira M; Romero P; Zudaire J; Moreno M; Ciérvide R; Aristu JJ; Martínez-Monge R
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):386-92. PubMed ID: 19427741
[TBL] [Abstract][Full Text] [Related]
9. [New anti-androgen and luteinizing hormone releasing hormone antagonist for the treatment of advanced prostate cancer].
Furuya Y; Masai M
Nihon Rinsho; 2000 Jul; 58 Suppl():317-9. PubMed ID: 11022739
[No Abstract] [Full Text] [Related]
10. [Neoadjuvant androgen ablation therapy (NAT)].
Kanetake H; Igawa T
Nihon Rinsho; 2000 Jul; 58 Suppl():320-2. PubMed ID: 11022740
[No Abstract] [Full Text] [Related]
11. [New possibilities in the hormonal therapy of metastatic carcinoma of the prostate].
Cicin-Sain D; Pasini J
Lijec Vjesn; 1989 Nov; 111(11):405-7. PubMed ID: 2699907
[TBL] [Abstract][Full Text] [Related]
12. [Hormonal treatments of prostate cancer].
Kuhn JM
Rev Prat; 1990 Nov; 40(25):2357-62. PubMed ID: 2124721
[No Abstract] [Full Text] [Related]
13. Prostate cancer drugs. Making sense of the options.
Mayo Clin Health Lett; 2003 Aug; 21(8):4-5. PubMed ID: 12971308
[No Abstract] [Full Text] [Related]
14. Multiple intracrine hormonal targets in the prostate: opportunities and challenges.
Labrie F
BJU Int; 2007 Jul; 100 Suppl 2():48-51. PubMed ID: 17594360
[No Abstract] [Full Text] [Related]
15. Re: luteinizing hormone-releasing hormone agonist effects on skeletal muscle: how hormonal therapy in prostate cancer affects muscular strength.
Marcora S; Oliver S; Callow N; Lemmey A; Stuart N
J Urol; 2005 Nov; 174(5):2068-9. PubMed ID: 16217402
[No Abstract] [Full Text] [Related]
16. Editorial comment.
Filson CP; Hollingsworth JM
Urology; 2013 Aug; 82(2):333-4; discussion 334. PubMed ID: 23896095
[No Abstract] [Full Text] [Related]
17. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
Chen RC; Sadetsky N; Chen MH; Carroll PR; D'Amico AV
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):36-9. PubMed ID: 19233568
[TBL] [Abstract][Full Text] [Related]
18. [Hormone therapy in prostate cancer: clinical results].
Morote-Robles J
Rev Esp Fisiol; 1990 Mar; 46(1):59-62. PubMed ID: 1697693
[TBL] [Abstract][Full Text] [Related]
19. Corticosteroid use after prostate brachytherapy reduces the risk of acute urinary retention.
Sacco DE; Daller M; Grocela JA; Babayan RK; Zietman AL
BJU Int; 2003 Mar; 91(4):345-9. PubMed ID: 12603412
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Kurko B
Urology; 2006 Jul; 68(1):116-20. PubMed ID: 16844453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
